On this page
The research desk’s view
A compounded injectable listing has inconsistent strength wording between its description and supply selector $180 per supply plus a stated $20 pharmacy shipping charge per order.
The listing, in detail
- Published service
- Provider-assessed care with a separate pharmacy shipping charge
- Product/menu scope
- A compounded injectable listing has inconsistent strength wording between its description and supply selector
- Cost position
- $180 per supply plus a stated $20 pharmacy shipping charge per order
- Decision condition
- Confirm exact product, individual eligibility and complete quote before a payment commitment
What the listing establishes
- A compounded injectable listing has inconsistent strength wording between its description and supply selector
- $180 per supply plus a stated $20 pharmacy shipping charge per order
What it leaves unanswered
- The description says 10 mg/mL in a 5 mL vial while the supply selector says 10 mg/5 mL. Those are materially different specifications. Do not resolve the discrepancy by choosing the more favorable interpretation. Ask the provider and dispensing pharmacy for the actual prescription label before comparing amount or value.
- A provider listing does not establish individual eligibility or a clinical benefit.
Where this comparison begins
IAM Health enters this comparison through a specific public listing: a compounded injectable listing has inconsistent strength wording between its description and supply selector The service describes provider-assessed care with a separate pharmacy shipping charge. That gives a reader a real place to begin asking questions, while leaving the clinical decision individual. It does not independently verify the pharmacy, establish that the product is appropriate or promise access. The starting evidence guide is useful background because the body's own MOTS-c signal and an administered product answer different research questions.
The important qualification
The description says 10 mg/mL in a 5 mL vial while the supply selector says 10 mg/5 mL. Those are materially different specifications. Do not resolve the discrepancy by choosing the more favorable interpretation. Ask the provider and dispensing pharmacy for the actual prescription label before comparing amount or value.
Put the first and later payments together
The public cost position is: $180 per supply plus a stated $20 pharmacy shipping charge per order. The written-quote comparison separates a medication amount from the costs of the wider care relationship.
What the evidence cannot supply
The distinction becomes clearer in the linked research appraisal. Its setting was rats with experimental type-2 diabetes, and the outcomes concerned cardiac structural/function measures and NRG1-ErbB-related expression. A shared pathway does not establish that a peptide provides the full effects of exercise. That observation helps a reader ask a narrower question of IAM Health: which human outcome evidence supports the exact proposal? A scientific reason for interest is not a forecast of a personal response, and a convenient care pathway does not turn the experimental system into a patient treatment trial.
Read another care pathway
For another service model, read the next provider comparison, which concerns surprise, Arizona clinic with walk-in access described for the practice. The point is to compare the care arrangement and remaining questions, not imply the same product or endorse a clinical outcome. A service with a clearer price can still have unresolved clinical suitability; a consultation with no product guarantee can still provide useful assessment. We have not measured patient experience, support speed or the quality of a supplied preparation at either service.
Read the source
Research findings and provider statements are different evidence.
- IAM Health official product or clinical-service pageCompany website